JR Pharma Engineering ApS: Financial statements 2023
CVR: 42398993
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
JR Pharma Engineering ApS (CVR 42398993) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 1,865,521 and a net result of DKK 645,284. The profit margin was 34.6%. Equity in the 2023 report amounted to DKK 687,226. The solvency ratio was 55.7%.
- Revenue
- DKK 1,865,521
- Gross Profit
- DKK 1,806,003
- Profit/Loss
- DKK 645,284
- Equity
- DKK 687,226
- Total Assets
- DKK 1,233,486
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout JR Pharma Engineering ApS
JR Pharma Engineering ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2021. The company is registered under the industry Rådgivende ingeniøraktiviteter inden for byggeri og anlægsarbejder. The management consists of Jimmy Rønne Jensen. The company is owned by JR Pharma Engineering Holding ApS. In 2026, the company reported revenue of DKK 2,000,220 and a net result of DKK 432,091 compared with DKK 591,630 the year before. Equity in the 2026 report amounted to DKK 474,033.